VIFOR-PHARMA
24.9.2020 07:02:06 CEST | Business Wire | Press release
Regulatory News:
Vifor Pharma today announced topline data from its AFFIRM-AHF study evaluating the effect of Ferinject® (intravenous ferric carboxymaltose) on heart failure hospitalizations and cardiovascular mortality in iron-deficient patients hospitalized for acute heart failure (AHF), compared to placebo. The trial narrowly missed statistical significance on its composite primary endpoint of reducing the risk of total heart failure hospitalizations and cardiovascular death. A pre-specified sensitivity analysis considering the impact of the COVID-19 pandemic, revealed a statistically significant difference in favor of Ferinject® on cardiovascular mortality and hospitalization for heart failure. The study results will be presented at the American Heart Association (AHA) congress in November this year.
“This trial makes a significant contribution to the growing body of evidence showing the importance of detecting and managing iron deficiency in heart failure”, said Prof Piotr Ponikowski, Principle Investigator and Head of the Department of Heart Diseases, Wroclaw Medical University and Head of the Center for Heart Diseases at the University Hospital, Wroclaw, Poland. “The totality of evidence from the trial suggests that treatment with intravenous ferric carboxymaltose of patients’ hospitalized due to AHF with concomitant iron deficiency is clinically beneficial. We look forward to presenting the detailed data to the scientific community.”
“We are delighted with the completion of the AFFIRM-AHF trial and are very encouraged by the results,” said Dr Klaus Henning Jensen, Chief Medical Officer Vifor Pharma. “Iron deficiency is a frequent, yet often unrecognized, co-morbidity in heart failure, present in approximately 50% of patients. Ferinject® is the only iron therapy included in the ESC guidelines to improve clinical symptoms and quality of life in heart failure patients with iron deficiency.”
AFFIRM-AHF is the first of three ongoing mortality and morbidity trials including FAIR-HF2 and HEART-FID to understand the full potential of Ferinject® in prolonging and improving quality of life of those suffering from heart failure and iron deficiency. AFFIRM-AHF was a randomized, double-blind placebo-controlled trial with 1,132 patients who had heart failure with reduced and mid-range ejection fraction (LVEF<50%) and iron deficiency (serum ferritin <100ng/mL or serum ferritin 100-299 ng/mL with TSAT <20%). Patients were randomized to receive either Ferinject® or placebo before being discharged from the hospital following an episode of AHF and followed for 52 weeks. Ferinject® was generally well tolerated and without unexpected safety findings.
Hospitalization due to AHF is the leading cause for hospital admissions in patients above 65 years old. Post-discharge outcomes are still poor with readmission rates exceeding 30% during the first 6 months post discharge and 1-year mortality above 20%. Iron deficiency is present in the majority of these patients and unfavorably impacts the outcomes.
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); and OM Pharma. Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit www.viforpharma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200923005818/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nebex Raises $30M Seed Round Led by GV to Build Market Infrastructure for the Global Space Economy29.6.2026 17:38:00 CEST | Press release
The new funding and banking relationship allow Nebex to scale the market and unlock the commercial space economy. Nebex, the market infrastructure platform for the global space economy, announced a $30M seed investment led by GV (Google Ventures), with participation from other top-tier venture funds. The company also announced a banking relationship with J.P. Morgan. The capital raise and new banking relationship will help Nebex scale its platform and connect sovereign space programs with the founders and companies building new technologies to serve the space industry. "We built Nebex because we've seen firsthand that ambitious space founders struggle to deliver complex sovereign programs due to the lack of capital markets infrastructure that supports revenue and cashflow. This is something that exists in nearly every other industry," said Tejpaul Bhatia, CEO of Nebex. "Support from these organizations gives Nebex the additional leverage and financial infrastructure to build the global
Medisca Enters Its Next Chapter Under Founder Antonio Dos Santos29.6.2026 16:19:00 CEST | Press release
Medisca today announced that Founder and Chairman Antonio Dos Santos has returned to the role of Chief Executive Officer as the company enters its next chapter of growth. For more than 35 years, Dos Santos has helped shape Medisca into a global leader in pharmaceutical compounding. As Chief Executive Officer, he will lead the company's long-term strategy, with a focus on expanding Medisca's global reach, investing in new areas of growth, strengthening strategic partnerships, and continuing to advance the products, services, education, and expertise that healthcare professionals rely on every day. "When I founded Medisca, my vision was to raise the standard of pharmaceutical compounding by bringing pharmaceutical-grade quality to the industry and giving healthcare professionals access to the products, knowledge, and innovation they needed to deliver better patient care," said Antonio Dos Santos, Founder and Chief Executive Officer of Medisca. "That purpose continues to guide us. As we b
The Premier Jumping League (PJL) & McCarthy Jumping Team Announce Landmark Purchase29.6.2026 15:10:00 CEST | Press release
With $50 Million Team Acquisition, McCarthy Jumping Team Becomes First PJL Ownership Group Acquisition illustrates strong investor confidence in the future of professional showjumping as highly anticipated 2027 inaugural season to feature 16 teams competing across 14 international events The Premier Jumping League (PJL) today announced that seasoned trader, investor, and competitive race car driver Jason McCarthy and McCarthy Jumping League LLC acquired the first PJL team in a landmark $50 million acquisition, building on rising momentum for the highly acclaimed professional jumping league. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629512997/en/ The Premier Jumping League (PJL), photographed by Daniel Benson. The milestone investment represents an unprecedented valuation for a team in a newly established sports competition and underscores the confidence that sophisticated investors are placing in the PJL. The inaugur
InvestEco Sustainable Food Fund IV Holds a Final Close With Total Commitments of C$106M29.6.2026 15:00:00 CEST | Press release
InvestEco Capital is pleased to announce the final close of the InvestEco Sustainable Food Fund IV. This fund will continue InvestEco’s work of investing in high-growth food companies that promote health and sustainability in the food sector. The Fund closed with total commitments of C$106M, the largest InvestEco fund to date. Investors include Farm Credit Canada, Export Development Canada, Business Development Bank of Canada, Fonds de solidarité FTQ, and two Government of Canada Social Finance Fund wholesalers: Boann and Realize Capital Partners. In addition, the Fund received commitments from a number of private investors and family offices. The Fund's investments to date include Humble Snacks, Little Sesame, Mid-Day Squares and Algae Cooking Club. The Fund expects to make a further 6 - 10 investments over the next few years. InvestEco Capital, founded in 2002, is a Toronto-based venture capital firm and impact investor focused on the sustainable food sector. For more information, em
Geoswift and SKUx Announce Strategic Partnership to Develop a First-of-Its-Kind Programmable Stablecoin Commerce Network29.6.2026 14:00:00 CEST | Press release
Bridging digital assets, traditional finance, enterprise treasury, and agentic commerce through global programmable money infrastructure Geoswift and SKUx announced a groundbreaking partnership to develop a next-generation programmable stablecoin commerce network. This strategic collaboration bridges digital assets, traditional finance, and real-world commerce at a global scale, representing a "one-of-one" opportunity by combining Geoswift's global infrastructure with SKUx's specialized item-level controls directly within point-of-sale (POS) systems. While enterprise stablecoin usage continues to accelerate globally, governments, enterprises, payment networks, and AI-driven commerce platforms are increasingly seeking programmable payment infrastructure that can bridge digital assets with real-world commerce. The innovation goes far beyond treasury management or even enabling consumers to spend stablecoins at retail locations. Instead, it unlocks true "programmable money" with embedded
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom